We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product c... Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004). Show more
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today...
Net cash provided by operating and investing activities was $15.8 million in the second quarter and net cash used by operating and investing activities was $57.3 million for the first six months...
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today...
Prothena to receive $80 million from Bristol Myers Squibb for exclusive global license to PRX019, a potential treatment of neurodegenerative diseases with an undisclosed target Prothena will...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -1.21 | -5.63314711359 | 21.48 | 22.25 | 20.08 | 487870 | 21.38443272 | CS |
4 | -1.54 | -7.06098120128 | 21.81 | 22.83 | 20.08 | 342924 | 21.38820447 | CS |
12 | 0.34 | 1.70597089814 | 19.93 | 25.42 | 19.04 | 370114 | 21.78025144 | CS |
26 | -4.8 | -19.1463901077 | 25.07 | 26.36 | 18.69 | 461934 | 21.76511505 | CS |
52 | -27.94 | -57.9547811657 | 48.21 | 55.89 | 18.69 | 629700 | 30.09056338 | CS |
156 | -55.61 | -73.286768582 | 75.88 | 79.749 | 18.69 | 528278 | 41.844796 | CS |
260 | 12.66 | 166.360052562 | 7.61 | 79.749 | 6.44 | 442728 | 36.87233604 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions